Finance

Lists
SDZXF:OTCMKTS
Sandoz Group AG
84,03 $
0,00%
(0,00) 1D
23 қыр., 15:20:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SDZXF...
Mkt. cap
31,82 млрд
Avg. vol.
122,00
Volume
13,67 мың
52-wk high
94,55 $
52-wk low
55,50 $
Shares outstanding
440,00 млн
No. of employees
20 мың
Mkt. cap
31,82 млрд
Avg. vol.
122,00
Volume
13,67 мың
52-wk high
94,55 $
52-wk low
55,50 $
Shares outstanding
440,00 млн
No. of employees
20 мың
News stories
From web sources and news partners
Profile
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars. Wikipedia
About Sandoz Group AG
CEORichard Saynor
Employees20 мың
Founded1886
Headquarters-
SectorPharmaceutical industry
Websitesandoz.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
2,95 млрд
2,95 млрд
2,89 млрд
2,89 млрд
Cost of goods sold
1,50 млрд
1,50 млрд
1,54 млрд
1,54 млрд
Cost of revenue
1,50 млрд
1,50 млрд
1,54 млрд
1,54 млрд
Research and development expenses
272,00 млн
272,00 млн
255,50 млн
255,50 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
668,50 млн
668,50 млн
683,50 млн
683,50 млн
Operating expense
1,02 млрд
1,02 млрд
1,23 млрд
1,23 млрд
Total operating expenses
2,52 млрд
2,52 млрд
2,77 млрд
2,77 млрд
Operating income
421,50 млн
421,50 млн
123,00 млн
123,00 млн
Other non operating income
-28,00 млн
-28,00 млн
-
-
EBT including unusual items
351,50 млн
351,50 млн
69,00 млн
69,00 млн
EBT excluding unusual items
367,50 млн
367,50 млн
69,00 млн
69,00 млн
Income tax expense
83,00 млн
83,00 млн
14,50 млн
14,50 млн
Effective tax rate
23,61%
23,61%
21,01%
21,01%
Other operating expenses
82,50 млн
82,50 млн
292,00 млн
292,00 млн
Net income
268,50 млн
268,50 млн
54,50 млн
54,50 млн
Net profit margin
9,11%
9,11%
1,88%
1,88%
Earnings per share
-
-
-
-
Interest and investment income
23,50 млн
23,50 млн
-
-
Interest expense
-54,50 млн
-54,50 млн
-54,00 млн
-54,00 млн
Net interest expenses
-31,00 млн
-31,00 млн
-54,00 млн
-54,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
531,00 млн
531,00 млн
256,00 млн
256,00 млн
Gain or loss from assets sale
-3,00 млн
-3,00 млн
-16,00 млн
-16,00 млн
AI content may include mistakes. Learn more
Google қолданбалары